Gilead Sciences Inc. is putting $25 million into Corus Pharma Inc., and has an option to buy the rest of the respiratory disease-focused firm down the road. (BioWorld Today)

Gilead Sciences Inc. is putting $25 million into Corus Pharma Inc., and has an option to buy the rest of the respiratory disease-focused firm down the road. (BioWorld Today)

Privately held Infinity Pharmaceuticals Inc. is getting a stock listing through a reverse merger with publicly traded Discovery Partners International Inc., to further the former's anticancer portfolio. (BioWorld Today)

Privately held Infinity Pharmaceuticals Inc. is getting a stock listing through a reverse merger with publicly traded Discovery Partners International Inc., to further the former's anticancer portfolio. (BioWorld Today)